Payments & FintechUK SME Merchant Payment Acceptance
A payments report needed evidence from behind the counter, so three hundred merchants were surveyed face to face across eleven categories.
The work, and what it settled
Twenty five engagements across four practices. Each one is the decision a client arrived with, the people we put the question to, and what the evidence let them do. Client names are withheld; nothing else is.
25 engagements · 4 practices · 19 sectors
Recent work
One from each practice
Client names are withheld. The question, the people we asked and what they found are not.
Payments & Fintech
Retail & CPGAir Purifiers, China Market Opportunity
Offline distributors earn about thirty percent gross margin against about ten for e-commerce. That gap was the route to market decision.
Pharma & BiotechOncology NGS Adoption and Whitespace
Adoption varies by testing model, and fifteen to twenty percent of the opportunity was still open across instrumentation, services and software.
Aftermarket ResearchBattery Replacement, Channel and Technology
First replacement is where the channel leaks. More than a hundred OEM authorized workshops explained how much stays in network, and why.
The archive
Everything else, by practice
Payments & FintechGlobal Merchant Payment Acceptance
Transaction data showed what merchants accepted but not why, so more than 13,000 of them were asked, on two frameworks across 28 countries.
Payments & FintechB2B Card Acceptance and Receivables
What card acceptance is worth to a large enterprise, quantified by the receivables and treasury leaders who would have to adopt it.
Payments & FintechSMB Pay and Get Paid Behavior
Some small businesses only pay suppliers, some only get paid, and some do both. Four markets of operators explained how each behaves.
Retail & CPGOTC Distribution, Three Markets
The same categories reach the shelf three different ways in Canada, Brazil and Mexico, so all three channel structures were walked and mapped.
Retail & CPGDairy Packaging, APAC
The white spaces in APAC dairy were not in the milk but in the pack, in single serve and multi pack formats that nobody had been asked about.
Retail & CPGHousehold Care, Twenty Markets
Twenty markets asked the same questions after the pandemic, to find which shifts in buying behavior had actually lasted.
Retail & CPGPlant Based Beverages, China
Oat milk leads in coffee because it barely affects the flavour. The question was which sub categories and occasions came next.
Retail & CPGInstant Noodles, US Launch
The lead flavour cleared sixty percent acceptance across three segments. The packaging still had work to do before launch.
Pharma & BiotechPractical AI Use Cases in Biopharma
Twelve peer leaders across clinical, regulatory and digital functions on where AI was adding value and what governance to expect.
Pharma & BiotechWhat Drives Laboratory Adoption
Eighty pathology and laboratory decision makers isolated the service, training and data integration factors that decide a purchase.
Pharma & BiotechMedTech Installed Base, India
One thousand sites visited center by center, capturing make, model and vintage across imaging equipment.
Pharma & BiotechCardiovascular Value Story Testing
Value messages, coverage assumptions and price corridors put in front of UK health plan and hospital decision makers before launch, not after.
Pharma & BiotechOncology Access Benchmark, Brazil
Reimbursement drivers, evidence expectations and pricing considerations across the Brazilian oncology landscape, set out as a comparative benchmark.
Pharma & BiotechRare Disease Pathway Barriers
Time to therapy is not lost in one place. Patients, caregivers and specialists mapped the delay across four stages in three markets.
Pharma & BiotechPhase III Data and Clinical Practice
KOLs and practicing oncologists on how differentiated upcoming data would look, and what it would actually move in the treatment algorithm.
Pharma & BiotechImmunology Care Model, Canada
A therapy still in development will arrive into a care model that already exists, so referral, sequencing and capacity were mapped first.
Pharma & BiotechImmunology Indication Prioritisation
Unmet need, priority patient segments and feasibility assessed with KOLs and payers, to give portfolio choices an evidence base.
Pharma & BiotechAsset and Partner Screening, Mexico
A shortlist tested on clinical relevance, commercial potential and execution risk, so diligence went only where it had been earned.
Pharma & BiotechSpecialty Care Competitor Perceptions
Competing brands compared on clinical confidence, access, service and messaging, to find the strengths to counter and the gaps to own.
B2B Channel ResearchVietnam LPG, Feasibility and Go to Market
A six week field program through Vietnamese LPG distribution, answering a go or no go entry question with market size, share and acquisition targets.
Aftermarket ResearchPrice Transmission and Distribution Economics
List price is not transacted price. Every tier of the value chain was interviewed and audited across the USA, Canada and Germany.
Payments & FintechUK SME Merchant Payment Acceptance
A payments report needed evidence from behind the counter, so three hundred merchants were surveyed face to face across eleven categories.
Retail & CPGAir Purifiers, China Market Opportunity
Offline distributors earn about thirty percent gross margin against about ten for e-commerce. That gap was the route to market decision.
Pharma & BiotechOncology NGS Adoption and Whitespace
Adoption varies by testing model, and fifteen to twenty percent of the opportunity was still open across instrumentation, services and software.
Aftermarket ResearchBattery Replacement, Channel and Technology
First replacement is where the channel leaks. More than a hundred OEM authorized workshops explained how much stays in network, and why.
Nothing in that practice yet.
Start here
Tell us the decision. We will tell you how to evidence it
Send us the question in a paragraph. A named research lead comes back with the angles worth covering, who we would put it to, and a timeline you can hold us to.